News/ News/ R&D Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-up Richard Staines epilepsy, Neurocrine, neurology, R&D, Xenon 0 Comment Two biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for Share X Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-up https://pharmaphorum.com/news/neurocrine-and-xenon-agree-1-75bn-epilepsy-rd-tie-up/
News/ News/ R&D Neurocrine slumps as Tourette’s drug fails clinical trial Phil Taylor Neurocrine, neurology, R&D, Tourette's 0 Comment Shares in Neurocrine Biosciences slumped by as much as a fifth after a much-anticipated trial in Tourette’s syndrome missed Share X Neurocrine slumps as Tourette’s drug fails clinical trial https://pharmaphorum.com/news/neurocrine-slumps-as-tourettes-drug-fails-clinical-trial/
